Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

IMPORTANCE: Agents targeting programmed cell death 1 (PD-1)/PD ligand 1 (PD-L1) improve long-term survival across many advanced cancers and are now used as adjuvant therapy for resected stage III and IV melanomas. The incidence and spectrum of chronic immune-related adverse events (irAEs) have not b...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Oncol
Main Authors: Patrinely, J. Randall, Johnson, Rebecca, Lawless, Aleigha R., Bhave, Prachi, Sawyers, Amelia, Dimitrova, Maya, Yeoh, Hui Ling, Palmeri, Marisa, Ye, Fei, Fan, Run, Davis, Elizabeth J., Rapisuwon, Suthee, Long, Georgina V., Haydon, Andrew, Osman, Iman, Mehnert, Janice M., Carlino, Matteo S., Sullivan, Ryan J., Menzies, Alexander M., Johnson, Douglas B.
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2021
Assuntos:
Brief Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7995124/
https://ncbi.nlm.nih.gov/pubmed/33764387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.0051
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares